This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy

This study has been terminated.
(Poor accrual.)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Quynh-Thu Le, Stanford University
ClinicalTrials.gov Identifier:
NCT00490061
First received: June 20, 2007
Last updated: January 13, 2017
Last verified: January 2017
  Purpose
We propose to combine lapatinib with RT alone in patients with locally advanced head and neck cancer who cannot tolerate chemotherapy. The main objective of the study is to determine the efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression (TTP) in this group of patients. In addition, we will determine the 2-year locoregional control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these patients. We will also evaluate the profile and frequency of late toxicity, specifically mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Condition Intervention Phase
Head and Neck Cancer Carcinoma, Squamous Cell Head and Neck Cancers Drug: Lapatinib Procedure: Radiotherapy (radiation) Device: G.E. Healthcare 1.5T MR, systems revision 12.0 M5 Device: DCE-MRI Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.

Resource links provided by NLM:


Further study details as provided by Quynh-Thu Le, Stanford University:

Primary Outcome Measures:
  • Progression Free Survival [ Time Frame: 2 year PFS: PFS at 2 yrs after study enrollment ]

    To determine the efficacy of combining lapatinib and radiotherapy in terms of Progression-free survival (PFS) in patients with locally advanced HNSCC who cannot tolerate concurrent chemoradiotherapy.

    Progression-free survival is defined is the time from starting treatment to the time of first documented tumor progression or death due to any cause, which ever occurs first.

    Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST V1.0) as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.



Secondary Outcome Measures:
  • Overall Survival. [ Time Frame: Two years survival rate after study enrollment ]
    Overall survival is the time from starting treatment until death due to any cause. For subjects who do not die, time to death will be censored at the time of last contact.


Enrollment: 17
Study Start Date: July 2007
Study Completion Date: June 2016
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Radiotherapy and Lapatinib with DCE-MRI
DCE-MRI will precede radiotherpy before and after Lapatinib loading. 1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy. Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.
Drug: Lapatinib
1500 mg po daily orally
Other Names:
  • Tykerb/Tyverb
  • GlaxoSmithKline
Procedure: Radiotherapy (radiation)
Standard of Care
Other Name: IMRT - Intensity Modulated Radiotherapy
Device: G.E. Healthcare 1.5T MR, systems revision 12.0 M5
Standard of Care, used to deliver IMRT
Other Name: G.E. Healthcare MRI Device and Software
Device: DCE-MRI
A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
Other Name: Dynamic contrast-enhanced magnetic resonance imaging

Detailed Description:

There is substantial data to suggest that EGFR and Her-2/neu expressions are important predictors for prognosis in HNSCC. EGFR blockade with a monoclonal antibody in conjunction with radiotherapy has been shown to improve survival over radiotherapy alone in patients with locally advanced HNSCC. Dual inhibition of EGFR and ErbB2 tyrosine kinases results in greater inhibitory effect of the downstream signaling pathways in cancer cells than inhibition of either receptor alone. Phase I studies in HNSCC suggested that the drug is well tolerated when delivered either alone or concurrently with cisplatin based chemoradiotherapy in HNSCC.

We propose to combine lapatinib with RT alone in patients with locally advanced HNSCC who cannot tolerate chemotherapy. The main objective of the study is to determine the efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression (TTP) in this group of patients. In addition, we will determine the 2-year locoregional control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these patients. We will also evaluate the profile and frequency of late toxicity, specifically mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with locally advanced HNSCC.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed stage III-IV HNSCC, pathologically confirmed (HNSCC from unknown primary sites are allowed)
  • No evidence of distant metastasis
  • No prior radiation therapy to the head and neck sites.
  • Able to sign a study-specific informed consent form.
  • Women of childbearing potential and men with partners capable of producing offspring must be willing to practice acceptable methods of birth control to prevent pregnancy.
  • Left ventricular ejection fraction (LVEF) within the institutional normal range as measured by ECHO (If ECHO cannot be performed or if the Investigator feels that it is not conclusive to evaluate LVEF, then a MUGA scan should be performed).
  • Having one of the following parameters that would preclude the use of concurrent CRT:

    • ECOG PS > 2.
    • Creatinine > 1.3 or calculate or measure creatinine clearance < 60 ml/min.
    • AST or ALT > 1.5 times normal limit but < 3 times normal limit
    • Total bilirubin > 1.5 mg/dL but < 3mg/dL
    • History of hearing loss that would preclude cisplatin chemotherapy. These would include the existing need of a hearing aid or a >= 25 decibel shift over 2 contiguous frequencies on a pretreatment hearing test.
    • Pre-existing peripheral neuropathy that would preclude cisplatin chemotherapy
    • Refuse or cannot tolerate chemotherapy
  • Age 18 years or older

Exclusion Criteria:

  • Known hypersensitivity to lapatinib or any of the excipients of this product (quinazolines).
  • Uncontrolled angina, arrhythmia or congestive heart failure at the time of HNSCC diagnosis and treatment.
  • History of myocardial infarction < 6 months from study entry.
  • Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.
  • Prior treatment with EGFR or Her2/Neu directed therapies.
  • HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with Lapatinib.
  • Absolute neutrophil count < 1500/uL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00490061

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
United States, Florida
University of Florida Shands Cancer Center
Gainsville, Florida, United States, 32610
United States, New York
Beth Israel
New York, New York, United States, 10003
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
United States, Wisconsin
University of Wisconsin Cancer Center
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Quynh-Thu Le
GlaxoSmithKline
Investigators
Principal Investigator: Quynh-Thu Le Stanford University
  More Information

Responsible Party: Quynh-Thu Le, Professor Radiation Oncology, Stanford University
ClinicalTrials.gov Identifier: NCT00490061     History of Changes
Other Study ID Numbers: ENT0020
97864 ( Other Identifier: Stanford University Alternate IRB Approval Number )
LAP #109855 ( Other Identifier: GlaxoSmithKline )
8857 ( Other Identifier: Stanford IRB )
Study First Received: June 20, 2007
Results First Received: November 11, 2016
Last Updated: January 13, 2017
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Head and Neck Neoplasms
Carcinoma, Squamous Cell
Neoplasms by Site
Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Lapatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 29, 2017